Atorvastatin and growth, rupture of small unruptured intracranial aneurysm: results of a prospective cohort study

Jie Wang, Jiancong Weng, Hao Li, Yuming Jiao, Weilun Fu, Ran Huo, Zihan Yan, Hongyuan Xu, Jiong Zhan, Shuo Wang, Xin Du, Yong Cao, Jizong Zhao, Jie Wang, Jiancong Weng, Hao Li, Yuming Jiao, Weilun Fu, Ran Huo, Zihan Yan, Hongyuan Xu, Jiong Zhan, Shuo Wang, Xin Du, Yong Cao, Jizong Zhao

Abstract

Background and aims: The role of statins in unruptured intracranial aneurysm (UIA) growth and rupture remains ambiguous. This study sought to determine whether atorvastatin is associated with aneurysm growth and rupture in patients harboring UIA <7 mm.

Methods: This prospective, multicenter cohort study consecutively enrolled patients with concurrent UIA <7 mm and ischemic cerebrovascular disease from four hospitals between 2016 and 2019. Baseline and follow-up patient information was recorded. Because of the strong anti-inflammatory effect of aspirin, patients using aspirin were excluded. Patients taking atorvastatin 20 mg daily were atorvastatin users. The primary and exploratory endpoints were aneurysm rupture and growth, respectively.

Results: Among the 1087 enrolled patients, 489 (45.0%) took atorvastatin, and 598 (55%) took no atorvastatin. After a mean follow-up duration of 33.0 ± 12.5 months, six (1.2%) and five (0.8%) aneurysms ruptured in atorvastatin and non-atorvastatin groups, respectively. In the adjusted multivariate Cox analysis, UIA sized 5 to <7 mm, current smoker, and uncontrolled hypertension were associated with aneurysm rupture, whereas atorvastatin [adjusted hazard ratio (HR) 1.495, 95% confidence interval (CI) 0.417-5.356, p = 0.537] was not. Of 159 patients who had follow-up imaging, 34 (21.4%) took atorvastatin and 125 (78.6%) took no atorvastatin. Aneurysm growth occurred in five (14.7%) and 21 (16.8%) patients in atorvastatin and non-atorvastatin groups (mean follow-up: 20.2 ± 12.9 months), respectively. In the adjusted multivariate Cox analysis, UIAs sized 5 to <7 mm and uncontrolled hypertension were associated with a high growth rate; atorvastatin (adjusted HR 0.151, 95% CI 0.031-0.729, p = 0.019) was associated with a reduced growth rate.

Conclusions: We conclude atorvastatin use is associated with a reduced risk of UIA growth, whereas atorvastatin is not associated with UIA rupture.The trial registry name:: The Clinic Benefit and Risk of Oral Aspirin for Unruptured Intracranial Aneurysm Combined With Cerebral IschemiaClinical Trial Registration-URL:: http://www.clinicaltrials.gov Unique identifier:: NCT02846259.

Keywords: atorvastatin; growth; risk factors; rupture; unruptured intracranial aneurysm.

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

© The Author(s), 2021.

Figures

Figure 1.
Figure 1.
The flow chart of the study patients. UIA, unruptured intracranial aneurysm.

References

    1. Backes D, Vergouwen MD, Tiel Groenestege AT, et al. PHASES score for prediction of intracranial aneurysm growth. Stroke 2015; 46: 1221–1226.
    1. Backes D, Rinkel GJE, Greving JP, et al. ELAPSS score for prediction of risk of growth of unruptured intracranial aneurysms. Neurology 2017; 88: 1600–1606.
    1. Vlak M, Algra A, Brandenburg R, et al. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis. Lancet Neurol 2011; 10: 626–636.
    1. Wiebers D, Whisnant J, Huston J, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 2003; 362: 103–110.
    1. Juvela S. Growth and rupture of unruptured intracranial aneurysms. J Neurosurg 2018; 131: 843–851.
    1. Malhotra A, Wu X, Forman H, et al. Growth and rupture risk of small unruptured intracranial aneurysms: a systematic review. Ann Intern Med 2017; 167: 26–33.
    1. Murayama Y, Takao H, Ishibashi T, et al. Risk analysis of unruptured intracranial aneurysms: prospective 10-year cohort study. Stroke 2016; 47: 365–371.
    1. Joo S, Lee S, Noh S, et al. What is the significance of a large number of ruptured aneurysms smaller than 7 mm in diameter? J Korean Neurosurg Soc 2009; 45: 85–89.
    1. Bellosta S, Ferri N, Bernini F, et al. Non-lipid-related effects of statins. Ann Med 2000; 32: 164–176.
    1. Jiang R, Zhao S, Wang R, et al. Safety and efficacy of atorvastatin for chronic subdural hematoma in Chinese patients: a randomized clinicaltrial. JAMA Neurol 2018; 75: 1338–1346.
    1. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001; 103: 276–283.
    1. Potey C, Ouk T, Petrault O, et al. Early treatment with atorvastatin exerts parenchymal and vascular protective effects in experimental cerebral ischaemia. Br J Pharmacol 2015; 172: 5188–5198.
    1. Schouten O, van Laanen JH, Boersma E, et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 2006; 32: 21–26.
    1. Schlösser F, Tangelder M, Verhagen H, et al. Growth predictors and prognosis of small abdominal aortic aneurysms. J Vasc Surg 2008; 47: 1127–1133.
    1. Wemmelund H, Høgh A, Hundborg HH, et al. Statin use and rupture of abdominal aortic aneurysm. Br J Surg 2014; 101: 966–975.
    1. Aoki T, Kataoka H, Ishibashi R, et al. Simvastatin suppresses the progression of experimentally induced cerebral aneurysms in rats. Stroke 2008; 39: 1276–1285.
    1. Kimura N, Shimizu H, Eldawoody H, et al. Effect of olmesartan and pravastatin on experimental cerebral aneurysms in rats. Brain Res 2010; 1322: 144–152.
    1. Yoshimura Y, Murakami Y, Saitoh M, et al. Statin use and risk of cerebral aneurysm rupture: a hospital-based case-control study in Japan. J Stroke Cerebrovasc Dis 2014; 23: 343–348.
    1. Marbacher S, Schläppi J, Fung C, et al. Do statins reduce the risk of aneurysm development? A case-control study. J Neurosurg 2012; 116: 638–642.
    1. Bekelis K, Smith J, Zhou W, et al. Statins and subarachnoid hemorrhage in Medicare patients with unruptured cerebral aneurysms. Int J Stroke 2015; (Suppl. A100): 38–45.
    1. Ní Chróinín D, Asplund K, Åsberg S, et al. Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational studies and randomized trials. Stroke 2013; 44: 448–456.
    1. Wang W, Jiang B, Sun H, et al. Prevalence, incidence, and mortality of stroke in China: results from a nationwide population-based survey of 480 687 adults. Circulation 2017; 135: 759–771.
    1. Wu S, Wu B, Liu M, et al. Stroke in China: advances and challenges in epidemiology, prevention, and management. Lancet Neurol 2019; 18: 394–405.
    1. Thompson B, Brown R, Amin-Hanjani S, et al. Guidelines for the management of patients with unruptured intracranial aneurysms: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2015; 46: 2368–2400.
    1. Fan C, Ouyang W, Tian L, et al. Elderly health inequality in China and its determinants: a geographical perspective. Int J Environ Res Public Health 2019; 16: 2953.
    1. Komukai K, Kubo T, Kitabata H, et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study. J Am Coll Cardiol 2014; 64: 2207–2217.
    1. Kajimoto K, Miyauchi K, Kasai T, et al. Short-term 20-mg atorvastatin therapy reduces key inflammatory factors including c-Jun N-terminal kinase and dendritic cells and matrix metalloproteinase expression in human abdominal aortic aneurysmal wall. Atherosclerosis 2009; 206: 505–511.
    1. Poulter NR, Prabhakaran D, Caulfield MJL. Hypertension. Lancet 2015; 386: 801–812.
    1. Vergouwen M, Rinkel G, Algra A, et al. Prospective randomized open-label trial to evaluate risk factor management in patients with unruptured intracranial aneurysms: study protocol. Int J Stroke 2018; 13: 992–998.
    1. Cochrane J, Chen H, Conigrave K, et al. Alcohol use in China. Alcohol Alcohol 2003; 38: 537–542.
    1. Sonobe M, Yamazaki T, Yonekura M, et al. Small unruptured intracranial aneurysm verification study: SUAVe study, Japan. Stroke 2010; 41: 1969–1977.
    1. Morita A, Kirino T, Hashi K, et al. The natural course of unruptured cerebral aneurysms in a Japanese cohort. N Engl J Med 2012; 366: 2474–2482.
    1. Bor A, Tiel Groenestege A, terBrugge K, et al. Clinical, radiological, and flow-related risk factors for growth of untreated, unruptured intracranial aneurysms. Stroke 2015; 46: 42–48.
    1. Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018; 392: 1036–1046.
    1. Hasan DM, Chalouhi N, Jabbour P, et al. Evidence that acetylsalicylic acid attenuates inflammation in the walls of human cerebral aneurysms: preliminary results. J Am Heart Assoc 2013; 2: e000019.
    1. García-Rodríguez LA, Gaist D, Morton J, et al. Antithrombotic drugs and risk of hemorrhagic stroke in the general population. Neurology 2013; 81: 566–574.
    1. Pottegard A, Garcia Rodriguez LA, Poulsen FR, et al. Antithrombotic drugs and subarachnoid haemorrhage risk. A nationwide case-control study in Denmark. Thromb Haemost 2015; 114: 1064–1075.
    1. Li W, Zhang Y, Tian Z, et al. Statin treatment for unruptured intracranial aneurysms study: a study protocol for a double-blind, placebo-controlled trial. Stroke Vasc Neurol. Epub ahead of print 6 May 2020. DOI: 10.1136/svn-2020-000353.
    1. Chien A, Liang F, Sayre J, et al. Enlargement of small, asymptomatic, unruptured intracranial aneurysms in patients with no history of subarachnoid hemorrhage: the different factors related to the growth of single and multiple aneurysms. J Neurosurg 2013; 119: 190–197.
    1. Gondar R, Gautschi OP, Cuony J, et al. Unruptured intracranial aneurysm follow-up and treatment after morphological change is safe: observational study and systematic review. J Neurol Neurosurg Psychiatry 2016; 87: 1277–1282.
    1. Villablanca J, Duckwiler G, Jahan R, et al. Natural history of asymptomatic unruptured cerebral aneurysms evaluated at CT angiography: growth and rupture incidence and correlation with epidemiologic risk factors. Radiology 2013; 269: 258–265.
    1. Backes D, Rinkel GJ, Laban KG, et al. Patient- and aneurysm-specific risk factors for intracranial aneurysm growth: a systematic review and meta-analysis. Stroke 2016; 47: 951–957.
    1. Juvela S, Poussa K, Lehto H, et al. Natural history of unruptured intracranial aneurysms: a long-term follow-up study. Stroke 2013; 44: 2414–2421.
    1. Greving JP, Wermer MJ, Brown RD, Jr., et al. Development of the PHASES score for prediction of risk of rupture of intracranial aneurysms: a pooled analysis of six prospective cohort studies. Lancet Neurol 2014; 13: 59–66.
    1. Jin D, Song C, Leng X, et al. A systematic review and meta-analysis of risk factors for unruptured intracranial aneurysm growth. Int J Surg 2019; 69: 68–76.
    1. Stirratt M, Dunbar-Jacob J, Crane H, et al. Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med 2015; 5: 470–482.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi